Lynozyfic (linvoseltamab-gcpt)

P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Dec 2025 --> Mar 2026

P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

We then summarize the clinical development and distinguishing features of currently approved BCMA-targeted modalities-CAR T-cell therapies (ide-cel, cilta-cel), bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab), and the antibody-drug conjugate (belantamab mafodotin)-highlighting their efficacy, toxicity profiles, and practical positioning in relapsed/refractory MM. Finally, we review emerging resistance mechanisms, including γ-secretase-driven sBCMA elevation, ligand-rich APRIL/BAFF niches, and therapy-induced TNFRSF17 lesions, ranging from biallelic deletions to epitope-altering missense mutations and in-frame deletions within the BCMA extracellular domain. These insights inform rational strategies such as γ-secretase inhibition, dual-target CAR T-cells and bispecific T-cell engagers.

P3, N=1000, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting

P3, N=915, Not yet recruiting, Regeneron Pharmaceuticals

P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Sep 2025 --> Dec 2025

P1/2, N=30, Not yet recruiting, Fred Hutchinson Cancer Center

P1/2, N=387, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2032 --> Jun 2033 | Trial primary completion date: May 2032 --> Mar 2033

P2, N=300, Not yet recruiting, Multiple Myeloma Research Consortium

P2, N=34, Not yet recruiting, Medical College of Wisconsin

P1, N=317, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2033 --> Sep 2034 | Trial primary completion date: Mar 2027 --> Apr 2028

P1, N=6, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Oct 2025 --> Mar 2028 | Trial primary completion date: Oct 2025 --> Mar 2028